Our expert in-house scientific team not only provides cutting-edge tumour models but also offers comprehensive compound testing through a range of advanced assays, tailored specifically to your modality or indication. Need something unique? We can develop custom assays to meet your precise needs. If you're looking for more relevant and efficient models for drug discovery and testing, reach out today for a complimentary consultation and discover how we can accelerate your research: https://lnkd.in/eWrrHpB8 🌟 #CancerResearch #DrugDiscovery #Bioprinting #Pharmaceuticals #CustomAssays #PreclinicalTesting #TumourModels
Carcinotech Ltd
Biotechnology Research
Edinburgh, Midlothian 3,532 followers
Reinventing Cancer Research
About us
Carcinotech has pioneered the development of assay-ready, 3D-bioprinted tumours derived from patient biopsies for oncology drug discovery and development. Carcinotech’s tumours are uniquely engineered to preserve cancer heterogeneity by encompassing multiple cell types present in the donor tumour microenvironment, including cancer, stromal, specialized microenvironment, immune, and cancer stem cells. This physiologically and genetically relevant model offers superior predictive power compared to traditional organoid and animal models, improving drug discovery, optimization, and pre-clinical testing efficiencies, thereby shortening the path to bringing a new oncology therapy to market.
- Website
-
http://www.carcinotech.co.uk
External link for Carcinotech Ltd
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Edinburgh, Midlothian
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Precision oncology, Cancer research, 3D bioprinting , Drug discovery , Cancer microenvironment, Personalised medicine testing, drug testing, oncology, assay services, biobank, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, immuno-oncology, early phase drug development, and immune cells
Locations
-
Primary
Roslin Innovation Centre
Easter Bush Campus
Edinburgh, Midlothian EH25 9RG, GB
Employees at Carcinotech Ltd
Updates
-
💡 Exciting breakthroughs in ovarian cancer treatment are on the horizon! Poly-adenosine ribose polymerase (PARP) inhibitors are a key component in cancer therapy, targeting a protein essential for repairing damaged DNA and preventing cancer cells from fixing themselves after chemotherapy. Despite their potential, these treatments can cause severe side effects and require dose reductions, which may compromise their efficacy. 🌟 New research from Moffitt Cancer Center demonstrates through mathematical modelling and in vitro experiments that PARP inhibitor therapy can be fine-tuned to align with the unique dynamics of a patient's tumour. The study's lead author notes, "Our findings suggest that modulation, rather than skipping doses, can halve the amount of drug used while maintaining its effectiveness. This approach reduces toxicity and can potentially delay the development of resistance." Moffitt's strategy not only improves treatment precision but also provides a more personalised and effective option for ovarian cancer patients, enhancing their prospects for better outcomes and quality of life. Read more: https://lnkd.in/eK_uJGHw #OvarianCancer #CancerResearch #PersonalisedMedicine #PARPInhibitors #BreakthroughTherapies
-
#ICYMI: check out the well-deserved recognition Carcinotech has received this summer! 🏆
Carcinotech Dominates Summer Awards Season
Carcinotech Ltd on LinkedIn
-
🎈Today is Carcinotech's 6th birthday! Over the past six years, we've been laser-focused on advancing and commercialising our novel platform to help biotech and pharmaceutical companies expedite the development of anti-cancer therapies. Thank you to our staff, investors, clients, and industry partners who have been fundamental to our growth. Here's to many more years of success 🥂🚀
-
-
A ground-breaking at-home pill for prostate cancer, Relugolix, is set to revolutionise patient care by providing an effective treatment that can be conveniently administered outside the hospital. This innovative development aims to enhance the quality of life and accessibility for patients, allowing them to receive vital medication in the comfort of their own homes. By potentially transforming the landscape of prostate cancer therapy, this advancement represents a significant step forward in the ongoing fight against the disease. Check out the full story on the Cancer Research UK (CRUK) website: https://lnkd.in/dqCiS3Cv
New ‘take at home’ prostate cancer pill approved by NICE
news.cancerresearchuk.org
-
In case you missed it! Check out this recap of our research paper published in Molecular Oncology.
Carcinotech Publishes Research on Patient-Derived 3D-Printed Tumours as a Breakthrough Tool for Drug Development
Carcinotech Ltd on LinkedIn
-
Scientists from Korea University have developed HVH-2930, a novel HSP90 inhibitor, which effectively induces apoptosis and overcomes treatment resistance in HER2-positive breast cancer. Unlike previous inhibitors, HVH-2930 bypasses the heat shock response, reducing toxicity. The inhibitor demonstrated significant efficacy in preclinical models, inhibiting tumour growth and enhancing the effects of paclitaxel. HVH-2930 could also potentially treat other HER2-overexpressing cancers, offering an affordable and accessible option for patients in resource-limited settings. For more details, you can read the full article here: https://lnkd.in/dESNwVr2 #Breast #Cancer #CancerResearch
Inhibitor overcomes drug resistance in HER2-positive breast cancer - Drug Discovery World (DDW)
https://www.ddw-online.com
-
Well done Michaela Macdonald! 🌟
Congratulations to Michaela Macdonald from Carcinotech Ltd for winning June's round of the #ResearchIsBeautiful campaign 👩🔬 Michaela's submission captures a 3D-bioprinted living tumour, derived from donor glioblastoma tissue and we think it's fantastic! Cancer Research UK Science and Innovation are now well into their third round and are keen to receive your submissions before 25 July. Find out in the comments how you can get involved 👇 Thank you to everybody who's entered so far and congratulations once again, Michaela 💙
-
-
Unlike conventional organoid models, Carcinotech Ltd's 3D-bioprinted tumours offer robust solutions for drug discovery and pre-clinical testing across all modalities—not just small molecules. Our tumours can be custom-engineered to replicate a wide range of solid tumour types, including rare cancers, ensuring precise modelling of the tumour microenvironment. This customisation, coupled with the modality-agnostic nature of our models, makes us a leading choice for advancing anti-cancer therapies efficiently and effectively. #CancerResearch #DrugDiscovery
-
-
It's been a busy summer for Carcinotech! We are proud to celebrate a season of exceptional achievements and recognition for our work in advancing cancer research. 🏆 Read our recent blog for a recap of the awards we've proudly received over the past few months: https://lnkd.in/eY_ys8uY #Innovation #CancerResearch #DrugDevelopment Enterprise Investment Scheme Association (EISA) Cancer Research UK Science and Innovation Cancer Research UK (CRUK) UK Business Angels Association
Carcinotech Dominates Summer Awards Season
https://www.carcinotech.co.uk